ZYKADIA 150 MG — DIN 02436779
CERITINIB : 150 MG · NOVARTIS PHARMACEUTICALS CANADA INC · CAPSULE · wholesale supply in Canada
Health Canada status: MARKETED
What is ZYKADIA?
ZYKADIA 150 MG contains CERITINIB : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02436779, held by NOVARTIS PHARMACEUTICALS CANADA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Apr-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ZYKADIA used for?
First-line treatment of ALK-positive locally advanced or metastatic NSCLC; treatment of ALK-positive locally advanced or metastatic NSCLC progressed on or intolerant to crizotinib.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Ceritinib cost around the world?
Ceritinib is listed on 11 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Czechia publishes a max producer price (ex-factory); Greece publishes a producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Greece | producer price (ex-factory) | 2 | 2 | EUR███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 2 | NOK███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Australia | ex-manufacturer | 1 | 1 | AUD███.██ |
| Czechia | max producer price (ex-factory) | 1 | 1 | CZK███.██ |
| Iceland | max wholesale | 1 | 1 | ISK███.██ |
| Italy | ex-factory (classe H) | 1 | 1 | EUR███.██ |
| Luxembourg | reimbursement | 1 | 1 | EUR███.██ |
| Romania | max producer price | 1 | 1 | RON███.██ |
| Saudi Arabia | public | 1 | 1 | SAR███.██ |
| South Africa | single exit price | 1 | 1 | ZAR███.██ |
13 pack listings across 12 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Ceritinib pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
| Pack configuration (monograph) | Blister packaging: 150 capsules (3 packs of 50 capsules). |
| Storage | Not explicitly stated in the provided text (refer to section 11 of full monograph). |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Ceritinib |
|---|---|
| ATC code | L01ED02 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02436779 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2436779 |
| Brand name | ZYKADIA |
| Generic / active ingredient | CERITINIB : 150 MG |
| Market authorization holder | NOVARTIS PHARMACEUTICALS CANADA INC |
| Health Canada schedule | Prescription |
| ATC code | L01ED02 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01ED |
| Current status | MARKETED |
| Status date | 29-Apr-2015 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended dose: 450 mg orally once daily with food. Swallow whole; do not chew or crush. Dose reductions in 150 mg decrements may be required for toxicity.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to ceritinib or any ingredient; congenital long QT syndrome; persistent QTcF >500 msec.
Warnings and precautions
Serious: QT interval prolongation, Interstitial Lung Disease/Pneumonitis (can be fatal), Hepatotoxicity, Gastrointestinal toxicity, and Hyperglycemia.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
2 · Same class — other molecules in ATC L01ED
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Brigatinib | ALUNBRIG | 4 | 4 | Yes |
| Crizotinib | XALKORI | 2 | 2 | Yes |
| Lorlatinib | LORBRENA | 2 | 2 | Yes |
| Alectinib | ALECENSARO | 1 | 1 | Yes |
| Ceritinib | ZYKADIA | 1 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01E
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01EX | Avapritinib · Cabozantinib · Capivasertib · Capmatinib · Entrectinib · +17 more | 80 | 64 |
| L01EA | Asciminib · Bosutinib · Dasatinib · Imatinib · Nilotinib · +1 more | 73 | 57 |
| L01EB | Afatinib · Dacomitinib · Erlotinib · Gefitinib · Lazertinib · +1 more | 40 | 23 |
| L01EF | Abemaciclib · Palbociclib · Ribociclib | 17 | 14 |
| L01EJ | Fedratinib · Momelotinib · Ruxolitinib | 8 | 8 |
| L01EE | Binimetinib · Cobimetinib · Selumetinib · Trametinib | 8 | 7 |
| L01EN | Erdafitinib · Infigratinib · Pemigatinib | 11 | 6 |
| L01EL | Acalabrutinib · Ibrutinib · Zanubrutinib | 10 | 5 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.